-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Non-transplant Treatment Approaches for High-risk TP53 Myeloid Disease

Program: Education Program
Session: Handling Bad News: How to Best Manage TP53 Myeloid Disease
Hematology Disease Topics & Pathways:
Research, Clinical trials, Translational Research, Clinical Research
Saturday, December 7, 2024, 4:00 PM-5:15 PM

Marina Konopleva

Albert Einstein College of Medicine, Houston, TX

Disclosures: Konopleva: AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: clinical trials, Research Funding; Vincerx: Consultancy; Servier: Speakers Bureau; Janssen: Consultancy, Other: clinical trials; Curis: Consultancy; Klondike Biopharma: Research Funding; Syndax: Membership on an entity's Board of Directors or advisory committees; Menarini Group: Consultancy, Membership on an entity's Board of Directors or advisory committees; Adaptive: Consultancy; Intellisphere: Speakers Bureau; Dark Blue Therapeutics: Membership on an entity's Board of Directors or advisory committees; MEI Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; Legend Biotech: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Auxenion GmbH: Membership on an entity's Board of Directors or advisory committees; Sanofi Aventis: Consultancy.